Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta-blockers in CHF: kidney's consequences].

G Cice1, S D'Isa

  • 1Seconda Università degli Studi di Napoli, Naples. gennarocice@hotmail.com

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|April 25, 2006
PubMed
Summary

Congestive heart failure (CHF) treatments evolved from hemodynamics to neurohumoral targets. While drugs like ACE inhibitors and beta-blockers benefit general populations, their efficacy in uremic patients requires further dedicated trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?

European review for medical and pharmacological sciences·2022
Same author

[Chronic heart failure treatment in uremic patients with beta-blockers].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2006
Same author

Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.

Journal of the American College of Cardiology·2001
Same author

Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study.

European heart journal·2000
Same author

[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].

Cardiologia (Rome, Italy)·2000
Same author

[Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis].

Cardiologia (Rome, Italy)·1999

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Context:

  • Congestive heart failure (CHF) understanding shifted from hemodynamic to neurohumoral mechanisms.
  • Neurohumoral activation is implicated in CHF pathophysiology and poor prognosis.
  • Current evidence for CHF therapies (ACE-I, beta-blockers, ARBs) primarily comes from the general population.

Purpose:

  • To review the evidence for neurohumoral-targeted therapies in congestive heart failure, particularly in uremic patients.
  • To highlight the lack of dedicated controlled trials in uremic populations for these treatments.
  • To emphasize the need for specific trials to guide clinical practice in cardiology and nephrology.

Summary:

  • Cardiovascular drugs targeting neurohumoral pathways, such as angiotensin-converting enzyme inhibitors (ACE-I), beta-blockers, and angiotensin II receptor blockers (ARBs), have shown efficacy in reducing morbidity and mortality in the general population with CHF.

Related Experiment Videos

  • However, robust evidence from prospective trials in uremic patients is lacking, despite retrospective analyses suggesting benefits for ACE-I and potential for greater benefit from beta-blockers due to sympathetic overactivation in uremia.
  • Further research, including specifically designed trials, is crucial to establish the efficacy and safety of these agents in patients with renal impairment.

    • Impact:

    • Identifies critical knowledge gaps in managing CHF in uremic patients.
    • Underscores the need for evidence-based guidelines tailored to this specific population.
    • Informs future research directions for cardiologists and nephrologists treating CHF with renal compromise.